These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 91468)

  • 1. N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.
    Stec GP; Atkinson AJ; Nevin MJ; Thenot JP; Ruo TI; Gibson TP; Ivanovich P; del Greco F
    Clin Pharmacol Ther; 1979 Nov; 26(5):618-28. PubMed ID: 91468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of procainamide and N-acetylprocainamide in renal failure.
    Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA
    Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of N-acetylprocainamide deacetylation.
    Stec GP; Ruo TI; Thenot JP; Atkinson AJ; Morita Y; Lertora JJ
    Clin Pharmacol Ther; 1980 Nov; 28(5):659-66. PubMed ID: 6160014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method.
    Atkinson AJ; Ruo TI; Piergies AA; Breiter HC; Connelly TJ; Sedek GS; Juan D; Hubler GL; Hsieh AM
    Clin Pharmacol Ther; 1989 Aug; 46(2):182-9. PubMed ID: 2474402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Acetyl-procainamide kinetics in the elderly.
    Galeazzi RL; Omar-Amberg C; Karlaganis G
    Clin Pharmacol Ther; 1981 Apr; 29(4):440-6. PubMed ID: 6162598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function.
    Drayer DE; Lowenthal DT; Woosley RL; Nies AS; Schwartz A; Reidenberg MM
    Clin Pharmacol Ther; 1977 Jul; 22(1):63-9. PubMed ID: 872496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of N-acetylprocainamide.
    Atkinson AJ; Ruo TI
    Angiology; 1986 Dec; 37(12 Pt 2):959-67. PubMed ID: 2433970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.
    Dutcher JS; Strong JM; Lucas SV; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1977 Oct; 22(4):447-57. PubMed ID: 902457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of coronary artery ligation on the pharmacokinetics of N-acetylprocainamide in dogs.
    Lai CM; Reynolds RD; Kamath BL; Calzadilla S; Gupta SD; Look ZM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):369-72. PubMed ID: 6158076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Acetylprocainamide kinetics after single and repeated oral doses.
    Ludden TM; Crawford MH
    Clin Pharmacol Ther; 1982 Mar; 31(3):343-9. PubMed ID: 6174262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
    Piergies AA; Ruo TI; Jansyn EM; Belknap SM; Atkinson AJ
    Clin Pharmacol Ther; 1987 Jul; 42(1):107-12. PubMed ID: 2439251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acetylprocainamide levels in patients with end-stage renal failure.
    Gibson TP; Matusik EJ; Briggs WA
    Clin Pharmacol Ther; 1976 Feb; 19(2):206-12. PubMed ID: 1261157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution of N-acetylprocainamide in rats.
    Yacobi A; Stampfli HF; Lai CM; Kamath BL
    Drug Metab Dispos; 1981; 9(3):193-5. PubMed ID: 6166443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.
    Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.